Eczema drug switch studied after first treatment fails
NCT ID NCT06773455
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a drug called tralokinumab could help adults with eczema who had already tried dupilumab and didn't get enough relief. The plan was to treat 20 people for 24 weeks, but the study was stopped early and only 7 people took part. The main goal was to see how many achieved clear or almost clear skin by week 16.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Psoriasis Treatment Center of New Jersey
East Windsor, New Jersey, 08520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common antibiotic boost eczema treatment?
- New biologic drug aims to clear stubborn eczema in just 24 weeks
- Skin disease evolution under the microscope: a 17-Year look at what drives severity
- Could a simple body wash and cream soothe eczema without a prescription?
- Skin sodium levels may hold clues to eczema in older adults
- Could a daily powder boost skin elasticity and fight fatigue?